Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Study acronym: CONCORD
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 42% 400 → 230 participants
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 400 → 230 participants Show 5 more changesShow less
    • Primary and study completion moved earlier from Nov 30, 2028 to Dec 31, 2027
    • Study sites: 26 to 28
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 7 of 16 entries
    • Study description expanded, about 37 words
  2. Re-verified, no change to tracked fieldsv9
  3. Trial sites expanded: 22 → 26 locationsv8
  4. Primary and study completion pushed from Jun 30, 2028 to Nov 30, 2028
    • Trial sites expanded: 18 → 22 locations
    v7
  5. Study sites: 17 to 18v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Study sites: 14 to 17v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary endpoints revised (15)
    • Study sites: 0 to 14
    • Secondary endpoints revised (16)
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
Prostate Cancer
2,562 trials monitored
See 170 trials at risk
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
Trial Details
NCT Number NCT07052578
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov